ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best emerging technology stocks to invest in. On December 18, Guggenheim analyst Yatin Suneja raised the firm’s price target on ABIVAX to $175 from $150 with a Buy rating on the shares. This sentiment was posted as the firm cited its optimistic outlook for obefazimod in the 44-week maintenance readout, which is currently upcoming.
On December 15, ABIVAX reported its financial results for Q3 2025. The company generated $2.40 million in revenue, surpassing Street estimates by $1.06 million. However, there was a loss per share that totaled $1.68 in the quarter. The net loss for the nine months widened to €254.1 million, up from €136.9 million in 2024 ($297.94 million and $160.52 million respectively). The company’s financial activity reflects an intensified focus on its lead candidate, obefazimod, a first-in-class…



